{"The": [0], "phase": [1], "III": [2, 14], "PACIFIC": [3], "trial": [4], "compared": [5], "durvalumab": [6, 26, 114, 165, 231, 270, 281, 294], "with": [7, 11, 29, 75, 95, 221, 269], "placebo": [8, 170, 233], "in": [9, 32, 310], "patients": [10, 163, 277, 290], "unresectable,": [12], "stage": [13], "non-small-cell": [15], "lung": [16], "cancer": [17], "and": [18, 54, 132, 146, 157, 204, 232, 246, 262, 265, 287, 297], "no": [19], "disease": [20, 300], "progression": [21], "after": [22, 88, 271], "concurrent": [23], "chemoradiotherapy.": [24, 272], "Consolidation": [25], "was": [27, 92], "associated": [28], "significant": [30], "improvements": [31], "the": [33, 89, 153, 222], "primary": [34, 223], "end": [35, 136], "points": [36], "of": [37, 83, 159, 167, 172, 175, 276, 289, 299, 308], "overall": [38], "survival": [39, 56, 148], "(OS;": [40], "stratified": [41, 64, 128, 142], "hazard": [42], "ratio": [43], "[HR],": [44], "0.68;": [45, 213], "95%": [46, 67, 194, 209], "CI,": [47, 68, 195, 210], "0.53": [48], "to": [49, 70, 113, 197, 212, 237, 242, 249, 254, 280, 293], "0.87;": [50], "P": [51, 72], "=": [52], ".00251)": [53], "progression-free": [55], "(PFS": [57], "[blinded": [58], "independent": [59], "central": [60], "review;": [61], "RECIST": [62], "v1.1];": [63], "HR,": [65, 192, 207], "0.52;": [66], "0.42": [69], "0.65;": [71], "<": [73], ".0001),": [74], "manageable": [76], "safety.": [77], "We": [78], "report": [79], "updated,": [80], "exploratory": [81], "analyses": [82, 138, 259], "survival,": [84], "approximately": [85], "5": [86, 285], "years": [87, 286], "last": [90], "patient": [91], "randomly": [93, 110, 161, 278, 291], "assigned.Patients": [94], "WHO": [96], "performance": [97], "status": [98], "0": [99], "or": [100, 126, 169], "1": [101, 107], "(any": [102], "tumor": [103], "programmed": [104], "cell": [105], "death-ligand": [106], "status)": [108], "were": [109, 139, 150, 234], "assigned": [111, 162, 279, 292], "(2:1)": [112], "(10": [115], "mg/kg": [116], "intravenously;": [117], "administered": [118], "once": [119], "every": [120], "2": [121], "weeks": [122], "for": [123, 230, 244, 256, 306], "12": [124], "months)": [125, 203, 218], "placebo,": [127], "by": [129], "age,": [130], "sex,": [131], "smoking": [133], "history.": [134], "Time-to-event": [135], "point": [137], "performed": [140], "using": [141, 152], "log-rank": [143], "tests.": [144], "Medians": [145], "landmark": [147], "rates": [149, 227], "estimated": [151, 274], "Kaplan-Meier": [154], "method.Seven": [155], "hundred": [156], "nine": [158], "713": [160], "received": [164], "(473": [166], "476)": [168], "(236": [171], "237).": [173], "As": [174], "January": [176], "11,": [177], "2021": [178], "(median": [179], "follow-up,": [180], "34.2": [181], "months": [182, 186], "[all": [183], "patients];": [184], "61.6": [185], "[censored": [187], "patients]),": [188], "updated": [189, 258], "OS": [190, 245, 264], "(stratified": [191, 206], "0.72;": [193], "0.59": [196], "0.89;": [198], "median,": [199, 214], "47.5": [200], "v": [201, 216], "29.1": [202], "PFS": [205, 267], "0.55;": [208], "0.45": [211], "16.9": [215], "5.6": [217], "remained": [219], "consistent": [220], "analyses.": [224], "Estimated": [225], "5-year": [226], "(95%": [228], "CI)": [229], "42.9%": [235, 275], "(38.2": [236], "47.4)": [238], "versus": [239, 251], "33.4%": [240], "(27.3": [241], "39.6)": [243], "33.1%": [247, 288], "(28.0": [248], "38.2)": [250], "19.0%": [252], "(13.6": [253], "25.2)": [255], "PFS.These": [257], "demonstrate": [260], "robust": [261], "sustained": [263], "durable": [266], "benefit": [268], "An": [273], "remain": [282, 295], "alive": [283, 296], "at": [284], "free": [298], "progression,": [301], "establishing": [302], "a": [303], "new": [304], "benchmark": [305], "standard": [307], "care": [309], "this": [311], "setting.": [312]}